Investigational drug · Phase 2
FT819
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "FT819"
First trial start
2026
Jul 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FT819", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Nephritis
- Systemic Lupus Erythematosus
- SLE - Systemic Lupus Erythematosus
- Lupus Nephritis - WHO Class III
- Lupus Nephritis - WHO Class IV
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "FT819" as an intervention, largest first.
Fate TherapeuticsIndustry
NCT06308978 · 244 participants (planned) · Start Mar 28, 2024 · Primary completion Sep 30, 2027
Drug: FT819; Fludarabine and 2 more · For: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Idiopathic Inflammatory Myositis (IIM); Systemic Sclerosis (SSc) and 2 more
Sites: Beverly Hills, California; Fullerton, California; Irvine, California · 21 sites in all
- FT819 in Subjects With B-cell MalignanciesActive, not recruiting
Fate TherapeuticsIndustry
NCT04629729 · 54 participants · Start Jul 12, 2021 · Primary completion Jun 18, 2025
Drug: FT819; Cyclophosphamide and 3 more · For: Lymphoma, B-Cell; Chronic Lymphocytic Leukemia; Precursor B-Cell Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Phoenix, Arizona; Davis, California · 18 sites in all
Fate TherapeuticsIndustry
NCT07570862 · 53 participants (planned) · Start Jul 27, 2026 · Primary completion Jul 1, 2029
Drug: FT819 · For: Lupus Nephritis; Systemic Lupus Erythematosus; SLE - Systemic Lupus Erythematosus and 2 more
Sites: Beverly Hills, California; Fontana, California; Fullerton, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Engineering Immune Effector Cells from iPSCs: From Reprogramming Biology to Next-Generation CAR Therapies.
Cabrera-Salcedo SC, García-Mantilla MD, Carrera-Suárez Y, et al. · Crit Rev Oncol Hematol 2026
- From Pluripotent Stem to CAR T Cells.
· Cancer Discov 2018
Also in development for Lupus Nephritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- IPG11406Phase 23 trials
Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.